# CatalYm

Source: https://onco.cc/companies/catalym/  
OnCo record `catalym` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CatalYm is a Germany-based biotechnology company running 5 late-stage cancer trials of Visugromab (CTL-002), Visugromab and visugromab (CTL-002) in non-small-cell lung cancer and hepatocellular carcinoma.

## Summary

CatalYm, based in Planegg-Martinsried, Germany, is a biotechnology company. A private, venture-backed cancer immunotherapy company developing antibodies that neutralise GDF-15, a mechanism cancers use to resist treatment, with its lead candidate visugromab. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing Visugromab (CTL-002), Visugromab and visugromab (CTL-002) in non-small-cell lung cancer and hepatocellular carcinoma. The largest, NCT07112196 (Visugromab in Cachexia International Trial), plans to enrol 518 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: CatalYm GmbH
- Tags: ctgov-sponsor
- HQ: Planegg-Martinsried
- Type: biotech
- Website: https://www.catalym.com

## Sources

- Official website: https://www.catalym.com
- ClinicalTrials.gov: trials led by CatalYm: https://clinicaltrials.gov/search?lead=CatalYm%20GmbH

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Visugromab](https://onco.cc/drugs/visugromab/)
- trials: [First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)](https://onco.cc/trials/nct04725474/), [Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC](https://onco.cc/trials/nct07246863/), [Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC](https://onco.cc/trials/nct07098988/), [Visugromab in Cachexia International Trial](https://onco.cc/trials/nct07112196/), [Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)](https://onco.cc/trials/nct07219459/)

---
JSON: https://onco.cc/api/v1/entities/catalym.json